Studies on the synthesis of S-peptides by furan and TMPRSS2
Despite a vaccine, there are still many unknowns that make it impossible for scientists to declare victory over the disease because of the many variants of COVID-19 and its ability to thwart efforts to eradicate it
But now, two Université de Montréal professors working at the Montreal Clinical Research Institute (IRCM) have taken a giant step forward in understanding the coronavirus: they have discovered and demonstrated the power of two small molecules that can stop the virus that causes COVID-19 SARS-CoV-2 infects cells in the lungs
The discovery was published Monday in the Journal of Virology by the team of Nabil G.
how it works and why
Virus entry into lung epithelial cells requires cleavage (↓) of the SARS-CoV-2 viral surface spike glycoprotein at two sites S1/S2 (PRRAR↓) and S2' (KPSKR↓), thereby exposing the host cell membrane and infectivity Fusion sequences for viral fusions
Seidah's team has been the first to predict that a 4-residue insertion (PRRA) in the spike sequence results in a canonical proprotein convertase furin-like cleavage at the S1/S2 sequence of PRRAR↓
The new study confirms the concept and clearly shows that furin cleaves at both sites, enhancing viral infection, the scientists said
RESULTS: Combining potent small molecule inhibitors furin (BOS compound) and TMPRSS2 (Camostat) blocked live virus-infected lung cells by more than 95%
Here's another weapon in the fight against COVID-19
SARS-CoV-2, the causative agent of COVID-19, has killed more than 6 million people globally, and the numbers are still rising
This is especially important as other coronaviruses are widely expected to emerge in the near future, they added